FDA approves Antares' Xyosted testosterone replacement therapy

FDA approved in October Xyosted from Antares Pharma Inc. (NASDAQ:ATRS) as a testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Antares expects launch the drug by year end. Xyosted is testosterone enanthate self-delivered once weekly using Antares' QuickShot subcutaneous autoinjector...